Connect with us

Science & Health

Feds Release Details About Contract To Roll Thousands Of Marijuana Joints

Published

on

There are just a few weeks left to send in an application to become a federally contracted preparer and distributor of research-grade marijuana.

And if a prospective applicant is still on the fence, the National Institute on Drug Abuse (NIDA) rolled out a 138-page solicitation notice last week that details all of the tasks the contractor will have to complete, including rolling thousands of “standardized marijuana cigarettes.”

The contract is meant to support NIDA’s research into the risks and benefits of various controlled substances and will last for five years starting in September, with the successful awardee receiving anywhere from $50,000 to nearly $20 million to get the job done.

There have been plenty of jokes about the opening, with some people volunteering for the job after media reports about it went viral. But in all seriousness, the criterion to receive the contract is strict. Individuals must be authorized to handle Schedule I drugs, pass a background check and have a facility that can adequately store and secure the research drug products. They must also be equipped to conduct thorough analyses on the substances’ purity, stability and dosage forms.

The selected contractor is barred from using “contract funds to support activities that promote the legalization of any drug or other substance included in schedule I of… the Controlled Substances Act, except for normal and recognized executive-congressional communications,” according to the notice.

That requirement isn’t necessarily imposed because the role involves working with controlled substances, though. Among other other general congressionally mandated riders attached to research contracts are bans on using funds “to maintain or establish a computer network unless such network blocks the viewing, downloading, and exchanging of pornography” or “to advocate or promote gun control.”

In any case, rolling thousands of joints is in fact a big part of the job. But just so you know, the contractor is explicitly prohibited from consuming any “material developed, modified, or delivered by or to the Government under this contract, or any subsequent modification of such material.”

NIDA outlines all of the various tasks required under the contract in a lengthy documents, but here are some of the highlights:

  • Manufacture, analyze, store, and ship marijuana cigarettes as required by NIDA
  • Acquire hard-to-find controlled and uncontrolled bulk drugs, and other chemical compounds of interest from DEA, commercial sources (including import from international sources), or any other source as required by NIDA.
  • Analyze cannabis materials and their preparations, such as Δ8 -tetrahydrocannabinol (delta-8-THC), Δ9 -tetrahydrocannabinol (delta-9-THC), cannabidiol, cannabichromene, cannabinol, and Δ9 -THC acids and determine their relative ratios in such preparations.
  • Develop and produce standardized reconstituted cannabis preparations, such as delta-9- tetrahydrocannabinol (Δ9 -THC), cannabis extract, cannabinoid parenteral, or any other dosage forms.
  • Prepare reference standards for qualitative and quantitative identification of cannabinoids and other drugs of abuse, prepare quantitative reference standards of cannabinoids and other drugs in serum or urine, and assess the stability of these preparations
  • Serve as NIDA’s drug repository, store controlled and uncontrolled drugs and other research chemical compounds, drug dosage forms, and marijuana and nicotine research cigarettes in proper storage conditions, such as in a secure, DEA approved vault, and in appropriate freezers as necessary
  • Determine the purity and stability of bulk drugs and other chemical compounds in the NIDA drug supply inventory periodically, or as required by the NIDA Contracting Officer’s Representative
  • Maintain active inventory of all required bulk drugs and other chemical compounds for research purposes
  • Store and ship bulk drugs and other chemical compounds for research as required by NIDA

Why is NIDA undertaking this contract? According to the agency, there has been a spike in demand for research-grade drug materials due to a “combination of factors, such as increased regulatory requirements that tend to discourage commercial availability and rapidly expanding research efforts in the area of drug abuse.”

“Therefore, the National Institute on Drug Abuse acquires, prepares/manufactures, analyzes, stores, bulk chemicals, drug dosage forms, including marijuana and nicotine research cigarettes, and makes them available to researchers for drug abuse and related research,” NIDA wrote.

The demand for marijuana is especially high. A sample of the task at hand calls for the manufacturing of joints of varying potency:

  • For proposal purposes, manufacture the following:
    25,000 Standardized marijuana cigarettes, Placebo (THC content, 0.0%)
    25,000 Standardized marijuana cigarettes, Low (THC content, 1.0-2.5%)
    25,000 Standardized marijuana cigarettes, Medium (THC content, 2.5 – 3.5%)
    50,000 Standardized marijuana cigarettes, High (THC content, 3.5 – 5.0%)
  • For proposal purposes, manufacture the following:
    25,000 Standardized marijuana cigarettes, Placebo (CBD content, 0.0%)
    25,000 Standardized marijuana cigarettes, Low (CBD content, 1.0-2.5%)
    25,000 Standardized marijuana cigarettes, Medium (CBD content, 2.5 – 3.5%)
    50,000 Standardized marijuana cigarettes, High (CBD content, 3.5 – 7.0%)
  • For proposal purposes, manufacture the following (by hand rolling):
    Produce 1,000 standardized marijuana cigarettes containing a high concentration of delta-9- THC, or cannabidiol (CBD) or both (greater than 5.0%) or as required by the NIDA COR.

It’s not exactly clear what’s behind the hand-rolling specification in the last bullet point above.

The deadline to submit applications is May 24, and contractors’ personnel must be prepared to pass background checks.

The EPA Is Funding Research On Using Hemp As A Sustainable Alternative To Concrete

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.

Kyle Jaeger is Marijuana Moment's Los Angeles-based associate editor. His work has also appeared in High Times, VICE and attn.

Science & Health

Two More Studies Show Patients Are Replacing Prescription Painkillers With Marijuana

Published

on

Two new studies out this month offer additional evidence that chronic pain patients are skipping addictive pharmaceuticals and using marijuana instead to help them find relief.

The findings are just the latest in an ever-growing body of research revealing cannabis’s potential to help address the country’s opioid crisis.

The first study, published in the International Journal of Drug Policy, aimed to investigate whether it’s “plausible” that people are substituting marijuana for opioids to help them with pain. Researchers from Florida International University used data from the National Survey on Drug Use and Health to evaluate whether people who live in states where medical cannabis is legal were less likely to turn to opioids for pain relief than those who lived in states where medical marijuana was not an option.

The researchers focused on several variables: whether respondents used or misused any prescription pain relievers during the past year, what states they lived in and whether those states had legalized cannabis for medicinal purposes, among other factors. The responses of 120,764 participants were analyzed for the years 2015 through 2017 of the survey.

According to the authors, “the results generated from the multivariate logistic regression equations show that [medical marijuana laws] are associated with a lower likelihood of opioid pain reliever use, but not misuse.”

“Results provide evidence that MMLs may be effective at reducing opioid reliance as survey respondents living in states with medical cannabis legislation are much less apt to report using opioid analgesics than people living in states without such laws, net other factors.”

These results, the study states, support other research that shows patients prefer to consume medical marijuana over opioids.

“In addition, cannabis enabled patients to reduce their reliance on opioids with a significant proportion indicating that cannabis was equal to opioids for pain relief and preferring cannabis over opioids if it were an available alternative,” it concludes. “Such subjective appraisals by patients are important in this context as the success of a treatment plan is in part determined by the patient’s perceptions of treatment efficacy and tolerance of side effects.”

The second study, published in PLoS ONE, took the question of whether or not patients substituted marijuana for prescription painkillers directly to the people. In a nationally representative survey of 16,280 adults, researchers from the San Francisco Veterans Affairs Medical Center asked participants to share information about their opioid and marijuana use. They also asked if they’d noticed a change in the amount of opiate medications they needed for pain because of marijuana use, and why patients who substituted cannabis for their prescription pain killers did so.

More than half of the people queried responded to the survey. Of the 9,003 respondents, 486 (5 percent) reported using marijuana and opioids in the past year; 43 percent said they took opioids daily and 23 percent reported consuming marijuana within the past month.

According to the study’s findings, 41 percent of that sample decreased or stopped using opioids because of marijuana use, while 46 percent reported no change in opioid use and 8 percent said they increased their opioid intake.

“We found that a substantial number of US adults reported that they substituted marijuana for opioids.”

“The most commonly reported reasons for substitution were better pain management (36%) and fewer side effects (32%) and withdrawal symptoms (26%), compared to the non-medical reasons for use: cheaper (13%) and more social acceptance from marijuana use (13%),” the study’s authors write.

“More research on this topic is clearly needed,” the study states. “Nonetheless, our findings suggest that even if objective measures do not support that marijuana is substitutive for opioid use, patients perceive that marijuana use has reduced their opioid use. Perhaps the commercialization of marijuana and the favorable media coverage surrounding the health effects of marijuana are fostering such a perception.”

Ultimately, both studies reveal the importance of patient-centered care in efforts to mitigate opioid use and misuse. That’s exactly what the Department of Health & Human Services (HHS) Pain Management Inter-Agency Task Force called for earlier this year.

Pilot Study Shows Marijuana Can Help Chronic Pain Patients Stop Taking Opioids

Photo courtesy of Martin Alonso.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading

Science & Health

A ‘Significant’ Number Of Patients Stopped Taking Benzodiazepines After Starting Medical Marijuana

Published

on

Nearly half of patients using marijuana to help with their respective medical conditions stopped taking prescribed benzodiazepines, a new study reports.

“Within a cohort of 146 patients initiated on medical cannabis therapy, 45.2% patients successfully discontinued their pre-existing benzodiazepine therapy,” the study’s authors write. “This observation merits further investigation into the risks and benefits of the therapeutic use of medical cannabis and its role relating to benzodiazepine use.”

While much research has been dedicated to understanding how medical cannabis could potentially replace opioids for patients who deal with chronic pain and other ailments, the new study suggests patients who take Valium, Xanax and other popular tranquilizers for neurological conditions (such as anxiety, insomnia and seizures) may find relief through marijuana. The findings were published last month in the journal Cannabis and Cannabinoid Research.

Researchers in Canada conducted a retrospective analysis of data collected from a group of patients who had been referred to the Canabo Medical Clinic for medical cannabis to treat a variety of medical conditions. They identified 146 patients who reported taking benzodiazepines regularly at the start of their cannabis therapy.

According to their findings, 44 patients (30 percent) had discontinued their benzodiazepines by their first follow-up visit. Another 21 had stopped the benzodiazepine treatment by their second follow-up visit, and one more person reported doing so at the third visit. All in all, 66 patients, or 45 percent of the sample, stopped taking benzodiazepines after starting a medical marijuana regimen.

“Patients initiated on medical cannabis therapy showed significant benzodiazepine discontinuation rates after their first follow-up visit to their medical cannabis prescriber, and continued to show significant discontinuation rates thereafter,” the study states. “Discontinuation was not associated with any measured demographic characteristic. Patients also reported decreased daily distress due to their medical condition(s) following prescription cannabinoids.”

The amount of CBD and THC content did not appear to play a role in who continued to discontinued taking the tranquilizers.

The design of the study, however, limited the authors’ ability to speculate about the mechanisms underscoring their results. Additionally, because they didn’t have access to information on what marijuana strains patients used or how they consumed it, the authors caution that their results can’t be generalized to what’s available in legal commercial markets today.

“The study results are encouraging, and this work is concurrent with growing public interest in a rapidly developing Canadian cannabis market,” said lead author Chad Purcell in a statement. “We are advising the public to observe caution. The results do not suggest that cannabis should be used an alternative to conventional therapies. Our purpose is inspiring others to advance current cannabis understanding as we collect stronger efficacy and safety data that will lead to responsible policy and recommended practices for use.”

The study also serves as an opportunity to draw more attention to the potential risks associated with benzodiazepines, Purcell told PsyPost. “I was interested in this project because it presented an opportunity to address benzodiazepines and cannabis use, both of which are becoming increasingly socially relevant. Benzodiazepines can be effective in treating many medical conditions but unlike opioids, there seems to be little public awareness of the risks associated with these commonly used prescription medications.”

According to the Centers for Disease Control and Prevention, overdose deaths related to benzodiazepines rose 830 percent between 1999 and 2017.

Patients Are Substituting Marijuana For Addictive Pharmaceutical Drugs, Two New Studies Show

Photo courtesy of Ndispensable

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading

Science & Health

Marijuana Legalization Doesn’t Cause Increased Crime, Federally Funded Study Finds

Published

on

Legalizing marijuana has little to no impact on rates of violent or property crime, according to a new study that was funded by a federal agency. The policy change did seem connected to a long-term decline in burglaries in one state, however.

While previous attempts to understand the relationship between legal cannabis markets and crime have turned up mixed results, researchers involved in this study used an enhanced methodology—a “quasi-experimental, multi-group interrupted time-series design”—to produce stronger evidence.

The study, published in the journal Justice Quarterly and funded by the federal National Institute of Justice, found that violent and property crimes rates were not affected in a statistically significant way in the years after Colorado and Washington State became the first in the nation to legalize marijuana for adult use.

“Our results suggest that marijuana legalization and sales have had minimal to no effect on major crimes in Colorado or Washington,” the paper concluded. “We observed no statistically significant long-term effects of recreational cannabis laws or the initiation of retail sales on violent or property crime rates in these states.”

The study authors explicitly cited claims made by prohibitionist group Smart Approaches to Marijuana and author Alex Berenson as being contradicted by their findings.

To determine the impact of legalization, researchers designed experimental models that compared crime rates in Colorado and Washington to those in 21 non-legal states from 1999 to 2016. The analysis was based on FBI data on violent, property, aggravated assault, auto theft, burglary, larceny and robbery crime rates.

Following legalization, there were one-time increases in property crime in the two states, as well as a spike in aggravated assault in Washington, but those did not reflect long-term trends, “suggesting that if marijuana legalization influenced crime, it was short-lived,” the study authors wrote.

Via Justice Quarterly.

Via Justice Quarterly.

There was one statistically significant long-term impact that the researchers did attribute to state marijuana laws: The burglary rate in Washington decreased, and that trend has held.

Via Justice Quarterly.

Via Justice Quarterly.

It’s not immediately clear why that is the case, and the study’s conclusion encourages future research that replicates and refines the design used for this experiment to solve answered questions.

“In summary, our results suggest that there may have been some immediate increases in crime at the point of legalization, yet there have been essentially no longterm shifts in crime rates because of legalization, aside from a decline in Burglary in Washington. Though the short-term increases might appear to suggest that marijuana increased crime, we caution against this interpretation as the increases do not reflect permanent shifts (that is, these are shifts in intercepts, not slopes) and could be artificially induced by the small number of time units between legalization and sales.”

Dale Willits, a study coauthor, said in a press release that in light of the “nationwide debate about legalization, the federal classification of cannabis under the Controlled Substances Act, and the consequences of legalization for crime continues, it is essential to center that discussion on studies that use contextualized and robust research designs with as few limitations as possible.”

“This is but one study and legalization of marijuana is still relatively new, but by replicating our findings, policymakers can answer the question of how legalization affects crime,” he said.

Study authors also noted that their analysis did not take into account other crimes such as drug impaired driving.

“Given the likelihood of further liberalization of state and even federal marijuana laws, it is imperative that policy makers and research funders allocate the necessary resources to conduct these more rigorous and intensive types of contextualized studies,” they concluded. “Large-scale policy shifts can take a considerable amount of time to produce stable and understandable effects.”

This is the second recent study that’s received Justice Department funding and arrived at a conclusion that runs against the logic of prohibition. Another example looked at the impact of legalization on law enforcement resources and trafficking trends.

Study Funded By Feds Debunks Myths About Marijuana Legalization’s Alleged Harms

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading
Advertisement

Stay Up To The Moment

Marijuana News In Your Inbox


Support Marijuana Moment

Marijuana News In Your Inbox

Do NOT follow this link or you will be banned from the site!